Literature DB >> 16401889

An estimate of the worldwide prevalence and direct costs of dementia in 2003.

A Wimo1, L Jonsson, B Winblad.   

Abstract

Dementia disorders are today considered to be a major driver of costs in health care and social systems and worrying estimates of future dementia prevalence have been presented. It is of great interest for policy makers to have an estimate of dementia disorders' contribution to global social and health care costs, particularly in light of the demographic prognoses. The worldwide costs of dementia were estimated from prevalence figures for different regions, and cost-of-illness studies from key countries using a model based on the relationship between direct costs of care per demented and the gross domestic product per capita in each country. The worldwide direct costs for dementia in 2003 are estimated at 156 billion USD in the main scenario based on a worldwide prevalence of 27.7 million demented persons (sensitivity analysis: 129-159 billion USD). Ninety-two percent of the costs are found in the advanced economies with 38% of the prevalence. Although there are several sources of uncertainty, it is obvious that the worldwide costs are substantial and the expected increase in elderly people in the developing countries presents a great challenge.

Entities:  

Mesh:

Year:  2006        PMID: 16401889     DOI: 10.1159/000090733

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  74 in total

1.  Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.

Authors:  A Gustavsson; L Jonsson; T Rapp; E Reynish; P J Ousset; S Andrieu; C Cantet; B Winblad; B Vellas; A Wimo
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia.

Authors:  A Wimo; L Jonsson; A Zbrozek
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 3.  Cognitive and memory training in adults at risk of dementia: a systematic review.

Authors:  Nicola J Gates; Perminder S Sachdev; Maria A Fiatarone Singh; Michael Valenzuela
Journal:  BMC Geriatr       Date:  2011-09-25       Impact factor: 3.921

4.  IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's Disease.

Authors:  A Gustavsson; L Jonsson; H Fillit; G Johansson; A Wimo; B Winblad
Journal:  J Nutr Health Aging       Date:  2010-05       Impact factor: 4.075

5.  Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial.

Authors:  Maud J L Graff; Myrra J M Vernooij-Dassen; Marjolein Thijssen; Joost Dekker; Willibrord H L Hoefnagels; Marcel G M Olde Rikkert
Journal:  BMJ       Date:  2006-11-17

Review 6.  Added therapeutic value of memantine in the treatment of moderate to severe Alzheimer's disease.

Authors:  T Heinen-Kammerer; H Rulhoff; S Nelles; R Rychlik
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 7.  Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified?

Authors:  Ben Seltzer
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers.

Authors:  Abdul H Fauq; Katherine Simpson; Ghulam M Maharvi; Todd Golde; Pritam Das
Journal:  Bioorg Med Chem Lett       Date:  2007-08-30       Impact factor: 2.823

9.  Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid-β.

Authors:  Tanusree Sen; Pampa Saha; Nilkantha Sen
Journal:  Sci Signal       Date:  2018-03-20       Impact factor: 8.192

10.  Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal.

Authors:  Liana G Apostolova; Lisa Mosconi; Paul M Thompson; Amity E Green; Kristy S Hwang; Anthony Ramirez; Rachel Mistur; Wai H Tsui; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2008-09-24       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.